ARKAY Therapeutics
1 Lexington Court
East Windsor
New Jersey
United States
Tel: 609-362-6818
Website: http://www.arkaytherapeutics.com/
About ARKAY Therapeutics
ARKAY Therapeutics is a privately-held pre-IND stage biopharmaceutical company located in East Windsor, NJ. We are dedicated to developing and commercializing personalized medicines for Type II diabetes, Prediabetes and metabolic disease-related disorders.YEAR FOUNDED:
2014
LEADERSHIP:
Founder & CEO: Dr. Ravi Kumar
JOBS:
Please click here for ARKAY job opportunities.
5 articles about ARKAY Therapeutics
-
ARKAY Therapeutics Announced as a Finalist in Most Successful Early Phase Research in 2019 Clinical & Research Excellence Awards
2/20/2019
ARKAY Therapeutics has been named a finalist in the Most Successful Early Phase Research (Preclinical and Phase I) category in the CARE Awards, which recognize outstanding work across the global clinical research enterprise.
-
The U.S. FDA Approves ARKAY Therapeutics’ IND Application for Evaluating RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product in Type 2 Diabetes Patients
6/5/2018
Human Proof-of-Concept (PoC) Trial to Evaluate the Superiority of RK-01 Over Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control.
-
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
4/11/2018
First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
-
ARKAY Therapeutics’ Announces Notice Of Allowance Of Patent Application For First-In Class “Beta-Cell-Centric” Drug, RK-01 For Type 2 Diabetes From The United States Patent Office
10/2/2017
-
Renowned Endocrinologist, Dr. Stan Schwartz, Regulatory Strategies Expert Dr. Nancy Motola And Formulations Expert, Dr. Hemant Joshi Join ARKAY Therapeutics’ Scientific Advisory Board
9/20/2016